References
- BAILLIE, T. A., NEILL, E., HUGHES, H., DAVIES, D. L. and DAVIES, D. S., 1979, Application of stable isotope labelling in studies of the metabolism of clonidine in rat liver. In Stable Isotopes: Proceedings of the Third International Conference (New York: Academic Press), pp 415–425.
- BALLARD, S. A., BURSLEM, F. S. M., GINGELL, C. J. G., PRICE, M. E., TANG. K., TURNER, L. A. and NAYLOR, A. M., 1996, In vitro profile of UK-92,480, an inhibitor of cyclic GMP-specific phosphodiesterase 5 for the treatment of male erectile dysfunction. journal of Urology, 155, 676A.
- BOOLELL, M., GEPI -ATTEE S., GINGELL, J. C. and ALLEN, M. J., 1996, Sildenafil, a novel effective treatment for male erectile dysfunction. British Journal of Urology, 78, 257–261.
- COOPER, J. D. H., MUIRHEAD, D. C., TAYLOR, J. E. and BAKER, P. R., 1997, Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromato-graphy. Journal of Chromatography B, 701, 87–95.
- JANN, M. W., GRIMSLEY, S. R., GRAY, E. C. and CHANG, W.-O., 1993, Pharmacokinetics and pharmacodynamics of clozapine. Clinical Pharmacokinetics, 24, 161–176.
- LOWRY, 0. H., ROSEBROUGH, N. M., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
- LUFFER -ATLAS, D., VINCENT, S. H., PAINTER, S. K., ARISON, B. H., STEARNS, R. A. and CHIC, S.-H. L., 1997, Orally active inhibitors of human leukocyte elastase. III. Identification and characterization of metabolites of L-694,458 by liquid chromatography-tandem mass spectrometry. Drug Metabolism and Disposition, 25, 940–952.
- MUIRHEAD, G. J., ALLEN, M. J., JAMES, G. C., PEARSON, J., RANCE, D. J., HOUSTON, A. C. and DEWLAND, P. M., 1996, Pharmacokinetics of sildenafil (ViagraT), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers. British Journal of Clinical Pharmacology, 42, 268P.
- OBACH, R. S., BAXTER, J. G., LISTON, T. E., SILBER, M., Jos, B. C., MACINTYRE, F., RANCE, D. J. and WASTALL, P., 1997, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics, 283, 46–58.
- OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
- RANCE, D. J., ATKINSON, F. M., JAMES, G. C., MACINTYRE, F. M., WALKER, D. K. and WASTALL, P., 1996, The pharmacokinetics of sildenafil after intravenous and oral doses to mouse, rat and dog. British Journal of Clinical Pharmacology, 42, 267P–268P.
- REMMER, H., SCHENKMAN, J. B., ESTABROOK, R. W., SASAME, H., GILLETTE, J. R., NARASEVIHULU, S., COOPER, D. Y. and ROSENTHAL, 0., 1966, Drug interactions with hepatic microsomal cytochrome. Biochemical Pharmacology, 48, 2147–2156.
- RING, B. J., CATLOW J, LINDSAY, T. J., GILLESPIE, T., ROSKOS, L. K., CERIMELE, B. J., SWANSON, S. P., HAMMAN, M. A. and WRIGHTON, S. A., 1996, Identification of the human cytochromes P450 responsible for the formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Journal of Pharmacology and Experimental Therapeutics, 276, 658–666.
- SMITH, D. A., 1987, Species variation in pharmacokinetics. In D. J. Benford, J. W. Bridges and G. G. Gibson (eds), Drug Metabolism: From Molecules to Man (London: Taylor & Francis), pp. 330–351.
- SMITH, D. A., 1991, Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metabolism Reviews, 23, 355–373.
- SMITH, D. A., HUMPHREY, M. J. and CHARUEL, C., 1990, Design of toxicokinetic studies. Xenobiotica, 20, 1187–1199.
- SMITH, D. A., JONES, B. C. and WALKER, D. K., 1996, Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Medicinal Research Reviews, 16, 243–266.
- TERRETT, N. K., BELL, A. S., BROWN, D. and ELLIS P., 1996, Sildenafil (ViagraTm), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorgank and Medicinal Chemistry Letters, 6, 1819–1824.